市場調查報告書

疾病分析:乾癬

Disease Analysis: Psoriasis

出版商 Datamonitor Healthcare 商品編碼 939974
出版日期 內容資訊 英文 88 Pages
商品交期: 最快1-2個工作天內
價格
疾病分析:乾癬 Disease Analysis: Psoriasis
出版日期: 2020年05月13日內容資訊: 英文 88 Pages
簡介

2019年,全球乾癬的患者數估算為5,260萬人,至2027年預計將增加到5,540萬人。

本報告提供全球乾癬市場相關調查分析,疾病的背景,治療,上市藥,開發平台醫藥品,臨床試驗,未來趨勢等相關的系統性資訊。

目錄

概要

疾病的背景

  • 定義
  • 症狀
  • 患者的分類
  • 患者的分類:各子類型

治療

  • 輕度外用製劑
  • 從中度到重症用全身療法
  • 外用製劑的等級
  • 主要的口服藥的等級
  • 主要的生物藥的等級
  • 治療指南

流行病學

  • 盛行率技術

上市藥

開發平台醫藥品

主要的法規趨勢

  • Mylan和Lupin
  • J&J的Stelara
  • FTC
  • Merger Plot Twist
  • AbbVie的Humira

成功的可能性

許可證、資產取得交易

臨床試驗形勢

  • 贊助商:各狀態
  • 贊助商:各階段
  • 最近的趨勢

醫藥品評估模式

市場動態

未來趨勢

共識的預測

最近的趨勢和分析師的見解

今後的主要趨勢

KOL的考察

參考文件

附錄

目錄
Product Code: DMKC0211548

Latest key takeaways

Datamonitor Healthcare estimates that in 2019, there were 52.6 million prevalent cases of psoriasis worldwide, and forecasts that number to increase to 55.4 million prevalent cases by 2027. First-line treatment of milder forms of psoriasis will continue to be with cheaper, topical medications. Use of more expensive systemic therapies will continue to be relegated to more severe psoriasis.

While the psoriasis market will see downward pressure from the arrival of biosimilars of the key marketed anti-TNF brands, Enbrel and Humira, overall growth will be driven partly by the recent launch of a number of more targeted interleukin inhibitors. Despite the fact that newer, targeted biologics show higher efficacy in psoriasis over TNF-alpha inhibitors, the latter are often maintained as first-line treatment due to existing contracts that involve savings with a wide range of label expansions, beyond spondyloarthropathies.

Results from head-to-head studies solidly place IL-17 and IL-23 inhibitors ahead of older TNF-alpha inhibitors in terms of efficacy, while differentiating between these newer pathways may come down to speed of disease clearance and safety signals. Because of a faster onset of action, IL-17-targeting drugs can differentiate from IL-23 inhibitors by touting a better cumulative effect, even though IL-23s win out at longer-term endpoints.

Positive read out from bimekizumab's three Phase III psoriasis trials, including head-to-head against Stelara and Humira, will ensure approval of UCB's IL-17A/F inhibitor. Unlike Novartis's Cosentyx and Eli Lilly's Taltz, which target IL-17A, UCB's bimekizumab neutralizes both IL-17A and IL-17F.

Topline results from the Phase III POETYK-PSO trials of Bristol Myers Squibb's TYK2 inhibitor BMS-986165, anticipated in 2020, are expected to substantiate the decision to offload Celgene's Otezla and allow the companies to proceed with the BMS-Celgene merger.

TABLE OF CONTENTS

OVERVIEW

  • Latest key takeaways

DISEASE BACKGROUND

  • Disease definition
  • Symptoms
  • Patient segmentation
  • Patient segmentation - subtypes

TREATMENT

  • Topical agents remain the gold standard for mild psoriasis
  • Systemic therapies are the mainstay of treatment for moderate-to-severe disease
  • Classes of topical agents to treat psoriasis
  • Key oral systemic classes to treat psoriasis
  • Major biologic classes to treat psoriasis
  • Treatment guidelines

EPIDEMIOLOGY

  • Prevalence methodology

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

  • Mylan And Lupin Get EU Etanercept Nod
  • J&J's Stelara Gets Europe OK For Pediatric Psoriasis
  • FTC Vote On BMS-Celgene Acquisition Splits Over Drug Pricing
  • In Merger Plot Twist, BMS Needs A Buyer For Celgene's Otezla, Raising New Questions
  • AbbVie's Humira Succession Plan Begins Taking Shape With Skyrizi US Approval

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Mundipharma Will Sell Samsung Bioepis' Biosimilars In Taiwan, Hong Kong
  • Dermavant Licenses Phase III Candidate To Japan Tobacco Affiliate
  • Amgen's $13.4bn Otezla Buy Helps Bristol/Celgene Merger Close By Year-End
  • China Ho! Sun Strikes Deals For Ilumya, Cequa
  • Alvotech And Fuji Stretch Alliance To Ustekinumab In Japan
  • As Expected: Shareholders Back Bristol's $74bn Celgene Buy

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

DRUG ASSESSMENT MODEL

MARKET DYNAMICS

FUTURE TRENDS

  • Recent biologic launches will drive growth in the psoriasis market
  • Head-to-head studies will help to position newer biologics
  • Oral agents struggle to demonstrate efficacy compared to biologics

CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION

  • Skyrizi for Psoriasis (January 14, 2020)
  • ARQ-151 for Psoriasis (January 6, 2020)
  • DUR-928 for Psoriasis (January 2, 2020)
  • Wynzora Cream for Psoriasis (December 18, 2019)
  • Bimekizumab for Psoriasis (December 6, 2019)
  • Bimekizumab for Psoriasis (November 15, 2019)
  • Bimekizumab for Psoriasis (October 17, 2019)
  • Inflectra for Psoriasis (September 19, 2019)
  • Otezla for Psoriasis (August 26, 2019)
  • Taltz for Psoriasis (August 13, 2019)
  • Multiple Drugs for Psoriasis (June 25, 2019)
  • Otezla for Psoriasis (June 24, 2019)
  • PPC-06 for Psoriasis (June 10, 2019)
  • Skyrizi for Psoriasis (April 23, 2019)
  • SensoReady Injector Pen for Psoriasis (April 9, 2019)

KEY UPCOMING EVENTS

KEY OPINION LEADER INSIGHTS

  • Quotes regarding newer treatments
  • Quotes regarding the IL-23 inhibitor advantage
  • Quote regarding an IL-17 inhibitor advantage
  • Quotes regarding endpoints and comparators in psoriasis

UNMET NEEDS

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of psoriasis, 2018-27
  • Figure 2: Overview of pipeline drugs for psoriasis in the US
  • Figure 3: Pipeline drugs for psoriasis, by company
  • Figure 4: Pipeline drugs for psoriasis, by drug type
  • Figure 5: Pipeline drugs for psoriasis, by classification
  • Figure 6: Probability of success in the psoriasis pipeline
  • Figure 7: Clinical trials in psoriasis
  • Figure 8: Top 10 drugs for clinical trials in psoriasis
  • Figure 9: Top 10 companies for clinical trials in psoriasis
  • Figure 10: Trial locations in psoriasis
  • Figure 11: Psoriasis trials status
  • Figure 12: Psoriasis trials sponsors, by phase
  • Figure 13: Datamonitor Healthcare's drug assessment summary for psoriasis
  • Figure 14: Market dynamics in psoriasis
  • Figure 15: Future trends in psoriasis
  • Figure 16: Skyrizi for Psoriasis (January 14, 2020): Phase III - vs. Secukinumab
  • Figure 17: ARQ-151 for Psoriasis (January 6, 2020): Phase IIb - Study 201
  • Figure 18: DUR-928 for Psoriasis (January 2, 2020): Trial Data - Suspension
  • Figure 19: Wynzora Cream for Psoriasis (December 18, 2019): Phase III - Europe
  • Figure 20: Bimekizumab for Psoriasis (December 6, 2019): Phase III - BE SURE
  • Figure 21: Bimekizumab for Psoriasis (November 15, 2019): Phase III - BE READY
  • Figure 22: Bimekizumab for Psoriasis (October 17, 2019): Phase III - BE VIVID
  • Figure 23: Taltz for Psoriasis (August 13, 2019): Phase IV - IXORA-R (vs. Tremfya)
  • Figure 24: PPC-06 for Psoriasis (June 10, 2019): Phase IIb - CD-004
  • Figure 25: Key upcoming events in psoriasis

LIST OF TABLES

  • Table 1: Psoriasis treatment guidelines
  • Table 2: Prevalent cases of psoriasis, 2018-27
  • Table 3: Marketed drugs for psoriasis
  • Table 4: Pipeline drugs for psoriasis
  • Table 5: Historical global sales, by drug ($m), 2014-18
  • Table 6: Forecasted global sales, by drug ($m), 2020-24
  • Table 7: Skyrizi for Psoriasis (January 14, 2020)
  • Table 8: ARQ-151 for Psoriasis (January 6, 2020)
  • Table 9: DUR-928 for Psoriasis (January 2, 2020)
  • Table 10: Wynzora Cream for Psoriasis (December 18, 2019)
  • Table 11: Bimekizumab for Psoriasis (December 6, 2019)
  • Table 12: Bimekizumab for Psoriasis (November 15, 2019)
  • Table 13: Bimekizumab for Psoriasis (October 17, 2019)
  • Table 14: Inflectra for Psoriasis (September 19, 2019)
  • Table 15: Otezla for Psoriasis (August 26, 2019)
  • Table 16: Taltz for Psoriasis (August 13, 2019)
  • Table 17: Multiple Drugs for Psoriasis (June 25, 2019)
  • Table 18: Otezla for Psoriasis (June 24, 2019)
  • Table 19: PPC-06 for Psoriasis (June 10, 2019)
  • Table 20: Skyrizi for Psoriasis (April 23, 2019)
  • Table 21: SensoReady Injector Pen for Psoriasis (April 9, 2019)